Sign in with Google. Opens in new tab
bearish
Vigil Neuroscience (VIGL US) IPO: Early-Stage First-Of-Its-Class Pipeline Makes It a Risky Bet
397 Views05 Jan 2022 16:43
SUMMARY
- Clinical-Stage biotech company, Vigil Neuroscience Inc (VIGL US) plans to offer 7 million shares at a price range of $15 to $17 per share in its upcoming IPO.
- The company is expected to price the IPO on January 6 and trade on January 7 on NASDAQ under the ticker symbol VIGL.
- The company developing antibody therapies for neurodegenerative diseases. Its lead candidate VGL101 is in phase 1 clinical trial, with topline data expected in H2 2022.
Related Insights
More »Loading
Trending Collections
More »Trending Insights
More »- Shin Kong (2888 TT)/Taishin (2887 TT) - Short Timer, FX Risk, Index Flows - Time To Buy Vs Peers
- S&P/ASX Indices: Proposed Methodology Changes & The BIG September Rebalance
- Defence Spending Is Not Stimulative
- Greatland Resources (GGP AU): Big Index Inclusions for Recent IPO
- Innovent Biologics Placement - Second for the Month, Stock Has Doubled but Momentum Is Strong
Top Unpaywalled Insights
More »- The New OS for Quant Finance: OpenBB, AI Agents & the Death of Legacy Terminals | New Barbarians ...
- Curator's Cut: Building Materials Moves, Benchmarking Gold Miners & Semaglutide in India and Japan
- [IO Technicals 2025/25] Bearish Momentum Strengthens
- VEON (VEON US): Launches Third Phase of Share Buyback Program After Share Pullback
- Valuations, Visas & Venture Pullback: An Equity + M&A Overview of the Education Sector in Q1 2025
Begin exploring Smartkarma's AI-augmented investing intelligence platform with a complimentary Preview Pass to:
- Unlock research summaries
- Follow top, independent analysts
- Receive personalised alerts
- Access Analytics, Events and more
Join 55,000+ investors, including top global asset managers overseeing $13+ trillion.
Upgrade later to our paid plans for full-access.
or
Already have an account? Sign In Now
Discussions
(Paid Plans Only)
Top Quartile
Tina Banerjee
Global Healthcare Analyst
Price Chart(Sign Up to Access)
- Vigil Neuroscience (VIGL US) IPO: Early-Stage First-Of-Its-Class Pipeline Makes It a Risky Bet05 Jan 2022
x